Kevin Lee Freeman Sells 7,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Health Catalyst Stock Down 1.2 %

Shares of HCAT opened at $7.29 on Friday. The stock’s 50-day moving average price is $6.87 and its 200 day moving average price is $6.93. The firm has a market capitalization of $430.37 million, a price-to-earnings ratio of -3.94 and a beta of 1.31. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.98.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. Health Catalyst’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.21) EPS. Equities research analysts expect that Health Catalyst, Inc. will post -0.37 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price target on shares of Health Catalyst in a research note on Tuesday, May 21st. Wells Fargo & Company decreased their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Friday, May 10th. Stephens dropped their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, August 20th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus price target of $11.42.

Hedge Funds Weigh In On Health Catalyst

A number of hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund increased its stake in Health Catalyst by 1.3% in the fourth quarter. New York State Common Retirement Fund now owns 122,967 shares of the company’s stock valued at $1,139,000 after acquiring an additional 1,582 shares during the period. Principal Financial Group Inc. boosted its holdings in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Health Catalyst by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after purchasing an additional 2,164 shares during the period. Quarry LP raised its holdings in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Health Catalyst by 23.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock worth $140,000 after buying an additional 2,817 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.